Table 9

Kidney

Author

Cases N

Controls_a/Cohort_b

Source Population

Exposure definition

Exposure assessment

Drug

RR

95% CI

McLaughlin et al. [63]

495*

697_a

Population based

More than 14 times per month for >36 months

Personal Interview

Aspirin (8%)

0.5^†

0.2–1.0

1.8^‡

0.7–4.1

McCredie et al. 1988[64]

360*

985_a

Population based

>0.1 kg lifetime use

Mailed questionnaire

Aspirin (18%)

1.2

0.7–1.9

McCredie et al.1995[65]

1,732*

2,309_a

Population based

>5 kg lifetime use

Personal Interview

Aspirin (5%)

1.2

0.9–1.7

Gago-Dominguez et al. [66]

1,201*

1,204_a

Population based

Two or more times a week for 1 month or longer

Personal Interview

Aspirin (27%)

1.5

1.2–1.8

Paganini-Hill et al. [40]

NR*

13,987_b

Cohort

Daily use of aspirin for an undefined time

Mailed Questionnaire

Aspirin (16%)

6.3

2.0–20.0

Schreinemachers et al. [43]

32

12,668_b

Cohort

Ever use of aspirin in the 30 days prior to start date

Personal Interview

Aspirin (59%)

0.60

0.29–1.24

*Renal cell carcinoma only; Prevalence of exposure among controls/cohort; ^†Male only; ^‡Female only.

González-Pérez et al. BMC Cancer 2003 3:28   doi:10.1186/1471-2407-3-28